Meeting
2014 ASCO Annual Meeting
A phase 1b study of ONT-380, an oral HER2-specific inhibitor, combined with capecitabine and trastuzumab, in HER2+ metastatic breast cancer (MBC).
Authors
Erika Paige Hamilton
Sarah Cannon Research Institute/Tennessee Oncology, Nashville, TN
Erika Paige Hamilton , Denise A. Yardley , Gabriel N. Hortobagyi , Luke N. Walker , Virginia F. Borges , Stacy L. Moulder
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer - HER2/ER
Track
Breast Cancer
Sub Track
HER2+
Clinical Trial Registration Number
NCT02025192
Citation
J Clin Oncol 32:5s, 2014 (suppl; abstr TPS663)
DOI
10.1200/jco.2014.32.15_suppl.tps663
Abstract #
TPS663
Poster Bd #
121B
Abstract Disclosures
Similar Posters
Poster
2015 ASCO Annual Meeting
Phase 1b study of ONT‑380, an oral HER2-specific inhibitor, in combination with capecitabine (C) and trastuzumab (T) in third line + treatment of HER2+ metastatic breast cancer (MBC).
First Author: Erika Paige Hamilton
Poster
2021 ASCO Annual Meeting
HER2CLIMB-04: Phase 2 open label trial of tucatinib plus trastuzumab deruxtecan in patients with HER2+ unresectable locally advanced or metastatic breast cancer with and without brain metastases (trial in progress).
First Author: Ian E. Krop
Poster
2021 ASCO Annual Meeting
Updated results of tucatinib versus placebo added to trastuzumab and capecitabine for patients with pretreated HER2+ metastatic breast cancer with and without brain metastases (HER2CLIMB).
First Author: Giuseppe Curigliano
Poster
2022 ASCO Annual Meeting
Phase 2 trial of tucatinib plus trastuzumab deruxtecan in patients with HER2+ locally advanced or metastatic breast cancer with and without brain metastases (HER2CLIMB-04, trial in progress).
First Author: Ian E. Krop